Drugs / lorundrostat
lorundrostat
also known as
LORUNDROSTAT HYDROBROMIDE · MLS-101 · MLS-101 FREE BASE · MLS-101 hydrobromide · MT-4129 · MT-4129 FREE BASE · MT-4129 hydrobromide
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02953132 | Nov 2016 → May 2017 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06785454 | Feb → Dec 2025 | essential hypertension, obstructive sleep apnea syndrome | Mineralys Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT06150924 | Dec 2023 → Feb 2025 | chronic kidney disease | Mineralys Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05769608 | Mar 2023 → Jan 2025 | hypertensive disorder | Mineralys Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05001945 | Jul 2021 → Sep 2022 | renal hypertension | Mineralys Therapeutics Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06153693 | Nov 2023 → Dec 2024 | hypertensive disorder | Mineralys Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05968430 | Jul 2023 → Dec 2025 overdue | hypertensive disorder | Mineralys Therapeutics Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lorundrostat | “Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial.” PMID 37690061 ↗ Sep 2023 |
| Known as | LORUNDROSTAT HYDROBROMIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095105 ↗ |
| Known as | MLS-101 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095105 ↗ |
| Known as | MLS-101 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095105 ↗ |
| Known as | MLS-101 hydrobromide | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095105 ↗ |
| Known as | MT-4129 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02953132 ↗ |
| Known as | MT-4129 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095105 ↗ |
| Known as | MT-4129 hydrobromide | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095105 ↗ |
| Action | Inhibit | “lorundrostat, an aldosterone synthase inhibitor” PMID 37690061 ↗ Sep 2023 |
| Modality | Small molecule | — CHEMBL5095105 ↗ |
| Route | Oral | “ascending single and multiple oral doses of MT-4129” NCT02953132 ↗ |